Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aspire Biopharma Holdings, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
ASBP
Nasdaq
2830
aspirebiolabs.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aspire Biopharma Holdings, Inc.
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))
- Feb 12th, 2026 6:00 am
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements
- Feb 11th, 2026 5:45 am
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Feb 10th, 2026 6:00 am
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit
- Feb 5th, 2026 6:00 am
Aspire Biopharma’s Buzz Bomb partners with Blue Shark Beverages
- Feb 4th, 2026 6:45 am
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution
- Feb 3rd, 2026 6:00 am
Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin
- Jan 29th, 2026 6:00 am
Aspire files patent application for clopidogrel sublingual powder formulation
- Jan 28th, 2026 6:26 am
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks
- Jan 27th, 2026 6:00 am
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity
- Jan 22nd, 2026 6:00 am
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign
- Jan 21st, 2026 6:00 am
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief
- Jan 20th, 2026 6:00 am
BC-Most Active Stocks
- Jan 14th, 2026 8:30 am
Aspire Biopharma Announces Reverse Stock Split
- Jan 14th, 2026 6:00 am
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
- Jan 7th, 2026 6:00 am
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine
- Dec 18th, 2025 6:30 am
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
- Dec 12th, 2025 3:00 pm
Aspire Biopharma Provides Q3 2025 Business Update
- Dec 4th, 2025 7:00 am
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
- Dec 2nd, 2025 7:00 am
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member
- Nov 26th, 2025 7:00 am
Scroll